Custom Services order now ship next day


The Phase II trial of baminercept (BG9924, LTβR-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. LTβR-Ig consists of the human LTβR extracellular domain fused to the human IgG1 Fc domain. It binds to LT α1/β2 and LIGHT ligands on activated lymphocytes and natural killer cells, blocking interactions with their receptors on peripheral antigen-presenting and stromal cells.
Protein class

Cancer-related genes, Plasma proteins

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Low cell type specificity

Immune cell specificity

Group enriched (classical monocyte, intermediate monocyte, non-classical monocyte, myeloid DC, neutrophil)

Cell line specificity

Cell line enhanced (HHSteC)


Self-associates. Associates with TRAF3, TRAF4 and TRAF5. (Microbial infection) Interacts with HCV core protein.

Molecular function


More Types Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

For Research Use Only. Not For Clinical Use.

© 2024 Creative Biolabs.
  • 0
  • 0

    Go to compare